MCID: CHL014
MIFTS: 60

Cholera

Categories: Gastrointestinal diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Cholera

MalaCards integrated aliases for Cholera:

Name: Cholera 12 76 53 59 55 43 3 44 15 73
Vibrio Cholerae 12 15
Cholera Due to Vibrio Cholerae 12
Cholera - Vibrio Cholerae 12
Vibrio Cholerae Infection 53

Characteristics:

Orphanet epidemiological data:

59
cholera
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),<1/1000000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:1498
ICD9CM 35 001 001.0 001.9
MeSH 44 D002771
SNOMED-CT 68 61972007 63650001
Orphanet 59 ORPHA173
MESH via Orphanet 45 D002771
UMLS via Orphanet 74 C0008354
ICD10 via Orphanet 34 A00.1 A00.9 A00.0
UMLS 73 C0008354

Summaries for Cholera

MedlinePlus : 43 Cholera is a bacterial infection that causes diarrhea. The cholera bacterium is usually found in water or food that has been contaminated by feces (poop). Cholera is rare in the US. You may get it if you travel to parts of the world with poor water and sewage treatment. Outbreaks can also happen after disasters. The disease is not likely to spread directly from person to person. Cholera infections are often mild. Some people don't have any symptoms. If you do get symptoms, they usually start 2 to 3 days after infection. The most common symptom is watery diarrhea. In some cases, the infection can be severe, causing lots of watery diarrhea, vomiting, and leg cramps. Because you quickly lose body fluids, you are at risk for dehydration and shock. Without treatment, you could die within hours. If you think that you might have cholera, you should get medical care right away. Doctors diagnose cholera with a stool sample or rectal swab. Treatment is the replacement of the fluid and salts that you lost through the diarrhea. This is usually with a rehydration solution that you drink. People with severe cases may need an I.V. to replace the fluids. Some of them may also need antibiotics. Most people who get fluid replacement right away will recover. There are vaccines to prevent cholera. One of them is available for adults in the U.S. Very few Americans need it, because most people do not visit areas that have an active cholera outbreak. There are also simple steps you can take to help to prevent cholera infection: Use only bottled or purified water for drinking, washing dishes, making ice cubes, and brushing your teeth If you do use tap water, boil it or use iodine tablets Wash your hands often with soap and clean water Make sure that the cooked food you eat is fully cooked and served hot Avoid unwashed or unpeeled raw fruits and vegetables Centers for Disease Control and Prevention

MalaCards based summary : Cholera, also known as vibrio cholerae, is related to pancreatic cholera and wdha syndrome, and has symptoms including fever and pruritus. An important gene associated with Cholera is ARF1 (ADP Ribosylation Factor 1), and among its related pathways/superpathways are GPCR Pathway and IL-2 Pathway. The drugs Formaldehyde and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, small intestine and colon, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A primary bacterial infectious disease that is described as an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae, which is characterized by profuse watery diarrhea, vomiting, leg cramps, circulatory collapse and shock.

NIH Rare Diseases : 53 Cholera is an infection of the small intestines that is caused by the bacterium Vibrio cholera. The condition can range from mild to severe and many affected people may have no obvious signs or symptoms. Approximately 5-10% of infected people will have severe disease with watery diarrhea and vomiting leading to rapid fluid loss, dehydration, and shock. If left untreated, this can cause acute renal failure, severe electrolyte imbalances, coma, or even death. People develop cholera when they eat food or drink water that is contaminated with Vibrio cholera. The condition occurs most often in places that lack water treatment and have poor sanitation and inadequate hygiene. Treatment aims to prevent dehydration and replace the fluids and salts that are lost through diarrhea.

Wikipedia : 76 Cholera is an infection of the small intestine by some strains of the bacterium Vibrio cholerae.... more...

Related Diseases for Cholera

Diseases related to Cholera via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 pancreatic cholera 12.5
2 wdha syndrome 12.0
3 vipoma 11.7
4 gastroenteritis 11.6
5 secretory diarrhea 11.4
6 diarrhea 10.5
7 cerebrotendinous xanthomatosis 10.4
8 pertussis 10.3
9 tropical calcific pancreatitis 10.2
10 dysentery 10.2
11 shigellosis 10.2
12 typhoid fever 10.2
13 influenza 10.2
14 acute diarrhea 10.1
15 spondyloocular syndrome 10.1
16 glioma 10.1
17 malaria 10.0
18 cholecystitis 10.0
19 cystic fibrosis 10.0
20 neuroblastoma 10.0
21 exanthem 10.0
22 salmonellosis 10.0
23 pasteurellosis 10.0
24 acalculous cholecystitis 10.0
25 plague 10.0
26 pneumonia 10.0
27 fasciitis 10.0
28 necrotizing fasciitis 10.0
29 acrocapitofemoral dysplasia 9.9
30 dengue virus 9.9
31 allergic conjunctivitis 9.9
32 erysipelas 9.9
33 tetanus 9.9
34 mouth disease 9.9
35 conjunctivitis 9.9
36 anthrax disease 9.9
37 smith-magenis syndrome 9.8
38 pancreatic cancer 9.8
39 helicobacter pylori infection 9.8
40 dengue disease 9.8
41 malignant glioma 9.8
42 pemphigus foliaceus 9.8
43 thrombosis 9.8
44 meningoencephalitis 9.8
45 bubonic plague 9.8
46 chlamydia 9.8
47 diphtheria 9.8
48 cellulitis 9.8
49 shwartzman phenomenon 9.8
50 gastritis 9.8

Graphical network of the top 20 diseases related to Cholera:



Diseases related to Cholera

Symptoms & Phenotypes for Cholera

UMLS symptoms related to Cholera:


fever, pruritus

GenomeRNAi Phenotypes related to Cholera according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 10.12 ARF4
2 Decreased viability GR00221-A-2 10.12 PLCB1
3 Decreased viability GR00221-A-3 10.12 PLCB1
4 Decreased viability GR00221-A-4 10.12 PLCB1
5 Decreased viability GR00240-S-1 10.12 ADCY10
6 Decreased viability GR00381-A-1 10.12 CD79A GNAS NEU1
7 Decreased viability GR00381-A-3 10.12 CD79A
8 Decreased viability GR00402-S-2 10.12 ADCY1 ADCY10 ARF1 ARF3 ARF4 ARF5
9 no effect GR00402-S-1 9.62 ADCY1 ADCY10 ARF1 ARF3 ARF4 ARF5

Drugs & Therapeutics for Cholera

Drugs for Cholera (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Formaldehyde Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-00-0 712
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable
12 Calcineurin Inhibitors Phase 4
13 Immunosuppressive Agents Phase 4
14 Methylprednisolone acetate Phase 4
15 Prednisolone acetate Phase 4
16 Cholera Toxin Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
17 Cyclosporins Phase 4
18
Ciprofloxacin Approved, Investigational Phase 3,Phase 1 85721-33-1 2764
19
Azithromycin Approved Phase 3 83905-01-5 55185 447043
20
Zinc Approved, Investigational Phase 3,Phase 1,Phase 2 7440-66-6
21
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
22 Acidophilus Phase 3
23 Topoisomerase Inhibitors Phase 3,Phase 1
24 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1
25 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 1,Phase 2
28 Micronutrients Phase 3,Phase 1,Phase 2
29 Trace Elements Phase 3,Phase 1,Phase 2
30 Erythromycin stearate Phase 3
31 Erythromycin Estolate Phase 3
32 Erythromycin Ethylsuccinate Phase 3
33 Antibodies Phase 3,Phase 2,Not Applicable
34 Immunoglobulins Phase 3,Phase 2,Not Applicable
35
Albendazole Approved, Vet_approved Phase 1, Phase 2 54965-21-8 2082
36
Secnidazole Approved Phase 1, Phase 2 3366-95-8
37
Zinc sulfate Approved, Investigational Phase 1, Phase 2 7733-02-0
38
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
39
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
40
Phenol Approved, Experimental Phase 1, Phase 2 108-95-2 996
41
Vitamin C Approved, Nutraceutical Phase 2,Phase 1 50-81-7 5785 54670067
42
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
43
Butyric Acid Experimental, Investigational Phase 2 107-92-6 264
44 Antiparasitic Agents Phase 1, Phase 2
45 Antimitotic Agents Phase 1, Phase 2
46 Astringents Phase 1, Phase 2
47 Antiprotozoal Agents Phase 1, Phase 2
48 Anthelmintics Phase 1, Phase 2
49 Dermatologic Agents Phase 1, Phase 2
50 Guar Phase 2

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines Completed NCT01949675 Phase 4
2 Evaluation of a Boosting Regimen With Oral Cholera Vaccine Completed NCT01579448 Phase 4
3 Bridging Study for Killed Oral Cholera Vaccine in Ethiopia Completed NCT01524640 Phase 4
4 A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children Completed NCT00760825 Phase 4
5 Mucosal Response in Immunocompromised Host Completed NCT01109914 Phase 4
6 Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Completed NCT00125008 Phase 4
7 New Hypo-Osmolar ORS (Recommended by WHO) for Routine Use in the Diarrhea Management– Surveillance Study for Adverse Effects Completed NCT00490932 Phase 4 Hypo-osmolar ORS
8 Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine Recruiting NCT03373669 Phase 4
9 CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera Recruiting NCT03705585 Phase 4 Vivotif Typhoid Oral Vaccine;Vaxchora
10 Blood Donor CVD 9000 Recruiting NCT03724357 Phase 4 Vaxchora
11 VAXCHORA Pediatric Study Active, not recruiting NCT03220737 Phase 4
12 Safety and Immunogenicity of a New Formulation of Euvichol® Unknown status NCT02502331 Phase 3
13 Randomized Controlled Field Trial of a Probiotics to Assess Its Role in Preventig Diarrhoea Unknown status NCT00534170 Phase 3
14 A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic Completed NCT02434822 Phase 3
15 Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh Completed NCT02027207 Phase 3
16 Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera Completed NCT01895855 Phase 3
17 Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata Completed NCT00289224 Phase 3
18 Ciprofloxacin Multiple Dose for Adult Cholera Completed NCT00741052 Phase 3 Ciprofloxacin;Azithromycin
19 Zinc Supplementation in Cholera Patients Completed NCT00226616 Phase 3 Zinc
20 Single Dose Azithromycin in the Treatment of Adult Cholera Completed NCT00229944 Phase 3 Azithromycin
21 Single Dose Ciprofloxacin in the Treatment of Childhood Cholera:Randomized Controlled Clinical Trial Completed NCT00142272 Phase 3 Ciprofloxacin
22 A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults Completed NCT02100631 Phase 3
23 A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults Completed NCT02094586 Phase 3
24 Oral Rehydration SolutionContaining Amylase Resistant Starch in Severely Malnourished Children. Completed NCT00324285 Phase 3 Amylase resistant starch added ORS
25 To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children Completed NCT02164110 Phase 3
26 Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children Completed NCT02556996 Phase 3
27 Improving Rotavirus Vaccine Immune Response Completed NCT01825109 Phase 3
28 A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants Completed NCT02133690 Phase 3
29 Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine Recruiting NCT03581734 Phase 3
30 Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Unknown status NCT00548054 Phase 2
31 Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Completed NCT02742558 Phase 2
32 Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata Completed NCT00119197 Phase 2
33 Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Completed NCT01233362 Phase 2
34 To Determine the Safety and Immunogenicity of an Oral Whole Cell ShanChol Cholera Vaccine in Bangladesh Completed NCT01042951 Phase 2
35 Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine Completed NCT02823899 Phase 1, Phase 2
36 Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Completed NCT00419133 Phase 2
37 Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine Completed NCT00128011 Phase 2
38 Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults Completed NCT00672308 Phase 2
39 Studies of Immune Responses to Orally Administered Vaccines in Developing Country Completed NCT01019083 Phase 1, Phase 2 Placebo;Placebo;Zinc Sulphate;Albendazole and Secnidazole
40 PXVX0200 (CVD103-HgR) vs Shanchol in Mali Completed NCT02145377 Phase 2
41 Field Application of Shanchol in Adults in Bangladesh Completed NCT01762930 Phase 2 Shanchol
42 Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults Completed NCT00741637 Phase 2
43 Slow Versus Rapid Rehydration of Severely Malnourished Children Completed NCT02216708 Phase 2
44 Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 Completed NCT03576183 Phase 2
45 Modified ORS Solution for Severely Malnourished Children Completed NCT01821586 Phase 2
46 Therapeutic Induction of Endogenous Antibiotics Completed NCT00800930 Phase 2
47 Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh Completed NCT02531802 Phase 1, Phase 2
48 Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Recruiting NCT03251495 Phase 2 Vaxchora
49 Extended Dose Intervals With Oral Cholera Vaccine in Cameroon Active, not recruiting NCT03719066 Phase 2
50 Vaccines and Dietary Oats in the Treatment of Ulcerative Colitis Terminated NCT00751933 Phase 2

Search NIH Clinical Center for Cholera

Cochrane evidence based reviews: cholera

Genetic Tests for Cholera

Anatomical Context for Cholera

MalaCards organs/tissues related to Cholera:

41
Skin, Small Intestine, Colon, Eye, T Cells, Testes, B Cells

Publications for Cholera

Articles related to Cholera:

(show top 50) (show all 2691)
# Title Authors Year
1
Killed Whole-Cell Oral Cholera Vaccine Induces CCL20 Secretion by Human Intestinal Epithelial Cells in the Presence of the Short-Chain Fatty Acid, Butyrate. ( 29434590 )
2018
2
Dynamics of Cholera Epidemics with Impulsive Vaccination and Disinfection. ( 29425779 )
2018
3
Cholera outbreak caused by drinking contaminated water from a lakeshore water-collection site, Kasese District, south-western Uganda, June-July 2015. ( 29949592 )
2018
4
Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. ( 29317118 )
2018
5
Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. ( 29414267 )
2018
6
Uptake and intracellular fate of cholera toxin subunit b-modified mesoporous silica nanoparticle-supported lipid bilayers (aka protocells) in motoneurons. ( 29339186 )
2018
7
Fucosylated molecules competitively interfere with cholera toxin binding to host cells. ( 29411974 )
2018
8
Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. ( 29942084 )
2018
9
Empirical antibiotic treatment for children suffering from dysentery, cholera, pneumonia, sepsis or severe acute malnutrition. ( 29790843 )
2018
10
Implementation research: reactive mass vaccination with single-dose oral cholera vaccine, Zambia. ( 29403111 )
2018
11
Surface Chemistry and Spectroscopic Study of a Cholera Toxin B Langmuir Monolayer. ( 29378405 )
2018
12
Cholera: an overview with reference to the Yemen epidemic. ( 29934743 )
2018
13
Use of cholera vaccines expands, raising hopes. ( 29439220 )
2018
14
A Systematic Review and Meta-Analysis of the Association between Water, Sanitation, and Hygiene Exposures and Cholera in Case-Control Studies. ( 29968551 )
2018
15
Oral cholera vaccine in cholera prevention and control, Malawi. ( 29904226 )
2018
16
Curbing cholera. ( 29899025 )
2018
17
Crisis-driven cholera resurgence switches focus to oral vaccine. ( 29962546 )
2018
18
The health economics of cholera: A systematic review. ( 29907482 )
2018
19
Probiotic strains detect and suppress cholera in mice. ( 29899022 )
2018
20
Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients. ( 29915319 )
2018
21
Systems, supplies, and staff: a mixed-methods study of health care workers' experiences and health facility preparedness during a large national cholera outbreak, Kenya 2015. ( 29890963 )
2018
22
A randomized, observer-blinded, equivalence trial comparing two variations of EuvicholAr, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines. ( 29895500 )
2018
23
No end to cholera without basic water, sanitation and hygiene. ( 29904216 )
2018
24
Long-run effects of early childhood exposure to cholera on final height: Evidence from industrializing Japan. ( 29349274 )
2018
25
Characterization of highly virulent multidrug resistant Vibrio cholerae isolated from a large cholera outbreak in Ghana. ( 29347965 )
2018
26
Places, attitudes and moments during the epidemics: representations of yellow fever and cholera in the city of Buenos Aires, 1867-1871. ( 29898124 )
2018
27
Cholera toxin enhances IL-17A production in both CD4<sup>+</sup>and CD8<sup>+</sup>cells via a cAMP/PKA-mediated IL-17A promoter activation. ( 29377102 )
2018
28
Comparative genomics of Vibrio cholerae O1 isolated from cholera patients in Bangladesh. ( 29981154 )
2018
29
Risk Factors for Self-Reported Cholera Within HIV-Affected Households in Rural Haiti. ( 29942825 )
2018
30
Human evolutionary loss of epithelial Neu5Gc expression and species-specific susceptibility to cholera. ( 29912959 )
2018
31
Cyclical cholera outbreaks in Ghana: filth, not myth. ( 29903037 )
2018
32
Temporo-spatial dynamics and behavioural patterns of 2012 cholera epidemic in the African mega-city of Conakry, Guinea. ( 29448965 )
2018
33
A live vaccine rapidly protects against cholera in an infant rabbit model. ( 29899024 )
2018
34
AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera. ( 29903911 )
2018
35
Vibrio cholerae OmpU induces IL-8 expression in human intestinal epithelial cells. ( 29145158 )
2018
36
A case of otitis externa caused by non-01/non-0139 Vibrio cholerae after exposure at a Mediterranean bathing site. ( 29791126 )
2018
37
Global well-posedness of infectious disease models without life-time immunity: the cases of cholera and avian influenza. ( 29088361 )
2018
38
Feasibility, coverage and cost of oral cholera vaccination conducted by icddr,b using the existing national immunization service delivery mechanism in rural setting Keraniganj, Bangladesh. ( 30261152 )
2018
39
Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique. ( 30281604 )
2018
40
A review of potential factors contributing to epidemic cholera in Yemen. ( 30285950 )
2018
41
Did you choose appropriate tracer for retrograde tracing of retinal ganglion cells? The differences between cholera toxin subunit B and Fluorogold. ( 30289890 )
2018
42
The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis. ( 30300420 )
2018
43
Inside Zimbabwe's efforts to tame cholera. ( 30303085 )
2018
44
Ending cholera for all. ( 30303093 )
2018
45
The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. ( 30314912 )
2018
46
Cholera epidemic in Yemen - Author's reply. ( 30316746 )
2018
47
Cholera epidemic in Yemen. ( 30316747 )
2018
48
The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination. ( 30319653 )
2018
49
Diarrhea Caused by Cholera? ( 30360651 )
2018
50
Reviving Phage Therapy for the Treatment of Cholera. ( 30395214 )
2018

Variations for Cholera

Expression for Cholera

Search GEO for disease gene expression data for Cholera.

Pathways for Cholera

Pathways related to Cholera according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
2
Show member pathways
13.18 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
3
Show member pathways
13.16 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
4
Show member pathways
13.05 ADCY1 CFTR EGF GNAI1 GNAS PLCB1
5
Show member pathways
13.02 ADCY1 CD79A EGF GNAI1 GNAS PLCB1
6 12.8 ADCY1 EGF GNAI1 GNAS PLCB1
7
Show member pathways
12.66 ARF1 ARF3 ARF4 ARF5 ARL1
8
Show member pathways
12.61 ADCY1 EGF GNAI1 GNAS PLCB1
9
Show member pathways
12.6 ADCY1 ARF6 EGF GNAI1 GNAS PLCB1
10
Show member pathways
12.53 ADCY1 EGF GNAI1 GNAS
11
Show member pathways
12.52 ADCY1 GNAI1 GNAS PLCB1
12
Show member pathways
12.5 ADCY1 GNAI1 GNAS PLCB1
13
Show member pathways
12.39 ADCY1 GNAI1 GNAS PLCB1
14
Show member pathways
12.37 ARF1 CFTR ERO1A GNAS TF
15 12.36 ARF1 ARF3 ARF5 ARF6
16
Show member pathways
12.35 ARF6 CFTR EGF TF
17
Show member pathways
12.33 ADCY1 GNAI1 GNAS PLCB1
18 12.32 ADCY1 GNAI1 GNAS PLCB1
19
Show member pathways
12.19 ADCY1 ARF1 ARF6 EGF GNAS PLCB1
20
Show member pathways
12.16 ADCY1 ADCY10 CFTR GNAI1 GNAS
21
Show member pathways
12.13 ADCY1 GNAI1 GNAS PLCB1
22
Show member pathways
12.12 ADCY1 CFTR GNAI1 GNAS
23 12.04 ADCY1 GNAI1 GNAS VIP
24 11.99 ADCY1 ADCY10 GNAI1 PLCB1
25
Show member pathways
11.98 ADCY1 GNAS PLCB1
26
Show member pathways
11.98 ADCY1 CFTR GNAI1 GNAS PLCB1
27 11.94 GNAI1 GNAS PLCB1
28 11.93 ADCY1 GNAI1 GNAS PLCB1
29
Show member pathways
11.91 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
30
Show member pathways
11.89 ADCY1 EGF GNAI1 PLCB1
31 11.87 ADCY1 EGF GNAI1 PLCB1
32 11.85 GNAI1 GNAS PLCB1
33 11.85 ADCY1 GNAS PLCB1
34 11.84 ADCY1 GNAI1 GNAS PLCB1
35 11.81 ADCY1 GNAI1 GNAS
36 11.78 ADCY1 CFTR GNAS PLCB1
37 11.69 ADCY1 CFTR GNAS
38 11.66 GNAI1 GNAS PLCB1
39 11.64 GNAI1 GNAS PLCB1
40 11.6 GNAI1 GNAS PLCB1
41 11.54 ADCY1 GNAI1 GNAS
42 11.5 GNAI1 GNAS PLCB1
43 11.5 ADCY1 EGF GNAI1 GNAS PLCB1
44 11.49 ADCY1 GNAI1 GNAS
45 11.43 ADCY1 GNAS PLCB1
46 11.37 ADCY1 GNAI1 GNAS PLCB1
47 11.36 ARF1 ARF5 ARF6
48 11.32 ADCY1 GNAS PLCB1
49 11.24 GNAI1 GNAS PLCB1
50 11.09 ADCY10 GNAI1 GNAS PLCB1

GO Terms for Cholera

Cellular components related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.8 ADCY10 ARF1 ARF3 ARF5 GNAS TF
2 lysosomal membrane GO:0005765 9.76 CFTR EGF GNAI1 NEU1
3 recycling endosome GO:0055037 9.65 ARF6 CFTR TF
4 intracellular GO:0005622 9.61 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
5 glutamatergic synapse GO:0098978 9.55 ADCY1 ARF1 ARF4 ARF6 PLCB1
6 extracellular exosome GO:0070062 9.44 ADCY1 ARF1 ARF3 ARF4 ARF5 ARF6
7 basal part of cell GO:0045178 9.43 ADCY10 TF
8 clathrin-coated vesicle membrane GO:0030665 9.43 CFTR EGF TF
9 membrane GO:0016020 10.28 ADCY1 ADCY10 ARF1 ARF4 ARF5 ARF6
10 plasma membrane GO:0005886 10.18 ADCY1 ADCY10 ARF1 ARF3 ARF4 ARF5

Biological processes related to Cholera according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein transport GO:0015031 9.88 ARF1 ARF3 ARF4 ARF5 ARF6
2 intracellular protein transport GO:0006886 9.73 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
3 membrane organization GO:0061024 9.67 CFTR EGF TF
4 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.61 ADCY1 GNAS VIP
5 retrograde vesicle-mediated transport, Golgi to ER GO:0006890 9.54 ARF3 ARF4 ARF5
6 cyclic nucleotide biosynthetic process GO:0009190 9.46 ADCY1 ADCY10
7 vesicle-mediated transport GO:0016192 9.43 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
8 cAMP biosynthetic process GO:0006171 9.4 ADCY1 ADCY10
9 cellular response to forskolin GO:1904322 9.33 ADCY1 CFTR GNAI1
10 activation of phospholipase D activity GO:0031584 9.32 ARF4 ARL1
11 Golgi to plasma membrane transport GO:0006893 8.92 ARF1 ARF3 ARF4 ARF5

Molecular functions related to Cholera according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.56 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
2 G-protein beta/gamma-subunit complex binding GO:0031683 9.37 GNAI1 GNAS
3 phosphorus-oxygen lyase activity GO:0016849 9.32 ADCY1 ADCY10
4 guanyl nucleotide binding GO:0019001 9.26 GNAI1 GNAS
5 GTPase activity GO:0003924 9.23 ARF1 ARF3 ARF4 ARF5 ARF6 ARL1
6 adenylate cyclase activity GO:0004016 9.16 ADCY1 ADCY10

Sources for Cholera

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....